• New Data for BRIUMVI (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment | Morningstar

    Source: Buzz FX / 18 Sep 2024 07:32:14   America/Chicago


    [GlobeNewswire](/news/globe-newswire) New Data for BRIUMVI (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment During year 5 of treatment wi
    Read more...
Share on,